Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?
This article was originally published in RPM Report
Executive Summary
Provenge and pirfenidone were two of the most closely watched pending applications at FDA. The agency's decision on the two therapies may offer some insight into the current regulatory climate.
You may also be interested in...
Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?
Pulmonary-Allergy Drugs: An Interview With FDA's Badrul Chowdhury
The Division of Pulmonary-Allergy Drugs has seen a number of high profile drugs come through its review group. The RPM Report sat down with Division Director Badrul Chowdhury to talk about his philosophy of drug review, the REMS, biosimilars, and the role of drug safety in making approval decisions.
Dendreon vs. CMS: "Full Coverage" or the CED Solution?
A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?